Analyst Corner: Maintain ‘add’ on GSK Pharma with TP of Rs 1,613

Company has impaired Vemgal by Rs 1.19 billion to reflect the estimated realisable value of Rs 1.8 billion at which it is being sold to Hetero. Hence, reported PAT declined 89.6% y-o-y. Adjusting for it PAT fell 20.0% y-o-y to Rs 1.0 billion.

from The Financial Express https://ift.tt/3wvMJDb
https://ift.tt/eA8V8J ICICI Securities